PURPOSE : To determine whether adding the multidrug resistance gene-1 ( MDR-1 ) modulator valspodar ( PSC 833 ; Novartis Pharmaceuticals , Hanover , NJ ) to chemotherapy provided clinical benefit to patients with poor-risk acute myeloid leukemia ( AML ) and high-risk myelodysplastic syndrome ( MDS ) .